Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...

Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Iterative Health will present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany, Feb. 19-22, 2025.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window For older ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

About a third of ulcerative colitis patients inadequately respond to anti-TNF drugs, necessitating treatment with other biologics or with JAK inhibitors, the researchers wrote. "Further research ...